Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Globus MedicalFRA:GM0N +0.17%98 EV-to-FCF is 14.97 as of Aug. 11, 2026, which is 62% below its 10-year median of 38.91. GuruFocus rates FRA:GM0N with a GF Score™ of 98/100 and a GF Value™ of €79.30 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 412 Medical Devices & Instruments companies, Globus Medical ranks better than 72.09% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Globus Medical's Enterprise Value is €9,591 Mil.
Globus Medical's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €641 Mil. Therefore, Globus Medical's EV-to-FCF for today is 14.97.
The historical rank and industry rank for Globus Medical's EV-to-FCF or its related term are showing as below:
FRA:GM0N'
s EV-to-FCF Range Over the Past 10 Years
Min: 12.96 Med: 38.91 Max: 73.73
Current: 14.86
During the past 13 years, the highest EV-to-FCF of Globus Medical was 73.73. The lowest was 12.96. And the median was 38.91.
FRA:GM0N's EV-to-FCF is ranked better than 72.09% of 412
companies
in the Medical Devices & Instruments industry
Industry Median: 24.855
vs FRA:GM0N: 14.86
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Globus Medical's PE Ratio (TTM) for today is calculated as:
Globus Medical's share price for today is €70.46.
Globus Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.363.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Globus Medical EV-to-FCF Related Terms
Globus Medical EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Globus Medical's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:GM0N vs PODD, BRKR, GKOS: EV-to-FCF Comparison
For the Medical Devices subindustry, Globus Medical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Globus Medical EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Globus Medical's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Globus Medical's EV-to-FCF falls into.
Globus Medical's current Enterprise Value is €9,591 Mil.
Globus Medical's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €641 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Globus Medical (FRA:GM0N) has a EV-to-FCF of 14.97 as of Aug. 11, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Globus Medical and its competitors. This is 62% below median its historical median of 38.91. Over the past decade, Globus Medical's EV-to-FCF has ranged from 12.96 to 73.73. According to the industry distribution chart, Globus Medical ranks #115 out of 412 companies in the Medical Devices & Instruments industry, placing it in the top 27.9%.
Is Globus Medical's EV-to-FCF too high?
Globus Medical's current EV-to-FCF of 14.97 is 62% below median its 10-year median of 38.91. Over the past 10 years, this metric has ranged from a low of 12.96 to a high of 73.73. The Medical Devices & Instruments industry median EV-to-FCF is 24.86. Globus Medical's value of 14.97 is 39.8% below this industry median. Based on the distribution chart, Globus Medical ranks #115 out of 412 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Globus Medical has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Globus Medical's EV-to-FCF compare to PODD and BRKR?
According to the Medical Devices & Instruments industry distribution chart, Globus Medical ranks #115 out of 412 companies for EV-to-FCF. This puts Globus Medical in the upper half of its industry. The industry median EV-to-FCF is 24.86. Globus Medical's value of 14.97 is 39.8% below this benchmark. Historically, Globus Medical's own EV-to-FCF has ranged from 12.96 to 73.73 over the past decade. While the company's 10-year median is 38.91 vs. the industry median of 24.86, Globus Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 24.86, based on 412 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Globus Medical's current EV-to-FCF of 14.97 is 39.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Globus Medical and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 24.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Globus Medical's current EV-to-FCF is 14.97, which is 62% below median its own 10-year median of 38.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Globus Medical stock overvalued right now?
Based on GuruFocus' analysis, Globus Medical (FRA:GM0N) is currently considered Modestly Undervalued. The stock's GF Value™ is €79.30, compared to a current price of €70.46 — trading 11.1% below its estimated fair value. The current EV-to-FCF is 14.97, which is 62% below median its 10-year median of 38.91 and 39.8% below the Medical Devices & Instruments industry median of 24.86. Globus Medical's overall GF Score™ is 98/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Globus Medical (FRA:GM0N), the current EV-to-FCF is 14.97 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Globus Medical (FRA:GM0N) Overvalued in 2026?
Based on GuruFocus' analysis, Globus Medical stock appears to be undervalued.
The current stock price of €70.46 is trading 11.1% below its estimated GF Value™ of €79.30.
GuruFocus considers Globus Medical to be Modestly Undervalued.
Key valuation signals for FRA:GM0N:
EV-to-FCF: 14.97 (62% below median its 10-year median of 38.91)
GF Value™: €79.30 vs. price of €70.46 (11.1% below fair value)
Industry Position: 39.8% below the Medical Devices & Instruments median (#115 of 412)
No single metric tells the full story. See the FRA:GM0N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
98GF Score
Get the complete analysis for FRA:GM0N
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GM0N has been successfully added to your 
